Amarin | AMRN - Przychody Ze Sprzedaży





Obroty Zmiana Data
AbbVie USD 15B 1.62B 2026-03
Alnylam Pharmaceuticals USD 1.17B 70M 2026-03
Amarin USD 49.22M 451K 2025-12
AstraZeneca USD 15.38B 90M 2026-06
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
DBV Technologies USD 645K 2.13M 2025-12
GlaxoSmithKline GBP 7.63B 991M 2026-03
Halozyme Therapeutics USD 377M 74.76M 2026-03
Heron Therapeutics USD 40.59M 2.38M 2025-12
Ionis Pharmaceuticals USD 246M 43M 2026-03
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 811M 5.5M 2026-03
Novartis USD 14.41B 1.3B 2026-06